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Major depression is the leading psychiatric disorder in developed countries, and the leading cause
of disability and burden of disease worldwide, with 350 million people currently being affected
(WHO, 2014). While treatment in the last decade has improved for stroke, cardiovascular disease,
and cancer, there has been little improvement in the pharmacological treatment of depression.
A majority of research funding is invested in the examination of pharmacological agents despite
known limitations of their efficacy (Penn and Tracy, 2012; Wilkinson and Izmeth, 2016). Current
treatment culture appears to be biased toward pharmacological treatment, possibly due to effective
marketing and ease of use for both clinicians and patients, while other forms of treatment,
albeit promising, receive less attention. The advancement of alternative treatment modalities is
specifically relevant to patient groups that are known to be vulnerable to the side effects of
antidepressants, e.g., the rapidly growing population of older adults with late-life depression
(Copeland et al., 2004; Vaughan et al., 2015) and pregnant and lactating women (Pearlstein, 2008).
The efficacy of transcranial magnetic stimulation (TMS) for the treatment of depression has
been demonstrated in numerous studies (Lefaucheur et al., 2014), while less evidence exists as to the
efficacy of transcranial electrical stimulation (tES), especially transcranial direct current stimulation
(tDCS) (Meron et al., 2015; Brunoni et al., 2016; Lefaucheur et al., 2017). The National Health and
Care Excellence (NICE, UK), in its interventional guidance procedure, updated at the end of 2015
and well regarded by other European countries, recommends TMS as a first-line treatment and
remarks on its good safety profile. Conversely, due to the inconsistency of results to date, NICE
recommends tDCS to be used only with special arrangement in the context of clinical practice
(www.nice.org.uk/guidance) and encourages further research.
An efficient and smooth translation of cutting-edge research findings into clinical applications
with the final end point of accessibility for patients requires a fast transition of knowledge, is
characterized by successful collaboration between clinicians, researchers, and policy makers, and
requires continuing refinement within and across each stage. This process involves the development
and improvement of intervention methods, testing in animal models and humans, and careful
development of clinical trials, before policy makers evaluate the given evidence and release
treatment guidelines. As the last and most important step for patient accessibility, national health
insurance entities decide on the integration of a givenmethod in their armamentarium of treatment
approaches. Although, it seems evident that an efficient translation from bench to bedside of novel
treatmentmethods, such as non-invasive brain stimulation (NIBS), is imperative in the fight against
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depression, such advancements are proceeding at a very leisurely
pace. However, besides this rather well-defined trajectory there
are other factors that account for the final accessibility of novel
treatment methods for patients, of which various appear to
hinder effective translation: Residency programs in psychiatry
offer only limited training in brain stimulation, resulting in
insufficient knowledge and awareness. In addition, lack of
infrastructure and resources in many hospitals prevents the
organization of an efficient treatment system. Finally, treatment
costs remain subject to differential health insurance policies
(Lefaucheur et al., 2014). Currently, several non-European
countries (USA, Canada, Brazil, Australia, Israel) approve the use
of TMS as a first- or second-line treatment in depression, while
few European (Germany, Finland, Serbia) countries reimburse
the costs of TMS treatment (Lefaucheur et al., 2014). The limited
translation of knowledge from bench to bedside gives rise to a
number of ethical issues. Firstly, patients are being forced to turn
to the growing number of private practices that offer off-label
treatment by therapists whomay lack certified training. Secondly,
the inadequate availability of NIBS treatments may encourage
seeking help from internet-based communities, and promote the
home-use of unapproved tES devices and protocols (Wurzman
et al., 2016). Thirdly, patients who are especially vulnerable
to side effects of pharmacological antidepressant treatments
continue to receive a non-optimal treatment, leading to increased
individual suffering and rising costs for society. In the case
of pregnant women, negative effects may also lead to further
adverse effects. For example, exposure to selective serotonin
reuptake inhibitors (SSRI) during pregnancy has been associated
with cognitive impairment in the offspring (Brown et al.,
2016). In older adults, efficacy of pharmacological treatment
is reduced (Wilkinson and Izmeth, 2016) and interactions
with other medication, as well as the physiological strain of
multimedication, pose an additional risk. In late-life depression,
a condition associated with an increased risk for dementia, even
a small improvement in depressive symptoms may lead to a large
advancement associated with secondary personal, familial, and
social benefits.
The above shortcomings and ethical issues require explicit
consideration when creating policies for the use of NIBS in
the treatment of depression. Factors responsible for slow
translation from research to clinical practice need to be
analyzed and addressed. Effective translation from bench to
bedside with the aim of increasing accessibility for patients
continues to require strong, ongoing support for research
seeking to enhance knowledge of the most effective way for
utilizing NIBS in treatment of depression. Translational efforts
should be encouraged via EU funding schemes specifically
dedicated to non-pharmacological research in depression
(e.g., industry-academy collaborations), the investigation of
underlying mechanisms and individual markers associated
with treatment success, as well as long-term follow-up of
effectiveness. Moreover, novel tES protocols such as transcranial
alternating current stimulation (tACS) and transcranial random
noise stimulation (tRNS), a special form of tACS (Antal and
Herrmann, 2016) as well as rTMS protocols such as accelerated
rTMS (McGirr et al., 2015) and theta-burst stimulation (Chung
et al., 2015) merit in-depth investigation.
The development of certified home-use devices, which
is specifically relevant for tES as it bears less risk than
rTMS, would further reduce costs and allow investigating
larger patient groups. However, this approach also requires
special attention with regards to misuse. Instead of approving
devices (such as Neuronetics in the U.S.A.), the approval
of specific protocols should be promoted and published in
international guidelines. This will lead to a market-driven cost
reduction, incite health insurances, and national health systems
to include NIBS as a treatment option, and consequently
improve access to NIBS treatments. More research in vulnerable
populations, particularly older adults and pregnant/lactating
women, and the explicit acknowledgment of these groups
in treatment guidelines is warranted. Furthermore, training
standards and guidelines need to be defined on a pan-European
level (Lefaucheur et al., 2017). Only adequately trained health
specialists should be allowed to offer NIBS treatment and training
in delivering NIBS interventions. These interventions should be
available not only through neurophysiologists but also through
psychologists and psychiatrists and constitute an integral part
of their general training requirements and ongoing education.
Implementation of active training approaches will consequently
lead to improvements in infrastructure and resources. Thus, joint
educational and research input from European universities is
needed to facilitate the effective development and application of
NIBS methods in treatment of depression.
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